The Medicines and Healthcare product Regulatory Agency (MHRA) has issued a positive opinion on tepotinib as a treatment for adult NSCLC patient whose tumours have METex14 skipping alterations ...
Six other drugs will have a concessional customs duty of 5% as part of efforts to increase accessibility of expensive advanced medicines for a larger section of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback